A prospective evaluation of hemoptysis cases in a tertiary referral hospital

Uzun, Oğuz; Atasoy, Yıldız; Fındık, Serhat; Atıcı, Atilla Güven; Erkan, Levent

doi:10.1111/j.1752-699x.2009.00158.x

Cited by 35 publications

(41 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer and pulmonary embolism are two of the most common causes of hemoptysis [33]. Also the bleeding risk of several lung cancer treatments like bevacizumab [34] and conventional myelosuppressive chemotherapy is well established.…”

Section: Discussionmentioning

confidence: 99%

Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer

Connolly

Dalal

Lin³

et al. 2012

Lung Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer

Connolly

Dalal

Lin³

et al. 2012

Lung Cancer

View full text Add to dashboard Cite

“…Lung cancer accounts for ∼20% to 30% of cases of PH, as manifested by haemoptysis [19–21]. Haemoptysis is among the most frequent presenting symptoms of lung cancer, being reported in ∼30% to 60% of patients in case series [22, 23].…”

Section: Ph In Patients With Nsclcmentioning

confidence: 99%

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

et al. 2012

View full text Add to dashboard Cite

Background:Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous non-small-cell lung cancer (NSCLC).Methods:A panel of expert oncologists, pulmonologists and radiologists reviewed the available data to identify predictive factors for PH in order to help guide physicians using bevacizumab in patients with NSCLC.Results:Patients with NSCLC are at an increased risk of PH owing to the underlying disease process. Patients with squamous histology and/or a history of grade ≥2 haemoptysis (≥2.5 ml per event) should not receive bevacizumab. No clinical or radiological features (including cavitation and central tumour location) reliably predict severe PH in bevacizumab-treated patients. Major blood vessel infiltration and bronchial vessel infiltration, encasement and abutting may predict PH; however, standardised radiological criteria for defining infiltration have not been established. Eligibility for bevacizumab is not affected by patient age, performance status or anticoagulation or antiplatelet therapy.Conclusions:An individualised risk–benefit assessment should be undertaken in all patients with NSCLC in whom bevacizumab is being considered. Further research is required to elucidate the mechanisms underlying PH and the clinical risk factors.

show abstract

“…There are a lot of pulmonary and systemic diseases reasons of hemoptysis, 5 however, to our knowledge, welding has not been listed as an etiology in any study. Alveolar hemorrhage due to welding fumes has never been defined before.…”

Section: Discussionmentioning

confidence: 90%

Massive hemoptysis due to welding fumes

Uzun

Ince

Bakalov

et al. 2012

Respiratory Medicine Case Reports

Self Cite

View full text Add to dashboard Cite

Many pulmonary problems such as lung cancer, occupational asthma, and pneumoconiosis have been described due to welding in the literature until now. This is the first case report of alveolar hemorrhage due to welding fumes presented with massive hemoptysis. We report a rare case of massive hemopthisis associated with welder’s lung, with a discussion based on a review of the literature.Established factsMany pulmonary diseases such as lung cancer, occupational asthma, and pneumoconiosis have been attributed welding fumes in the literature. Alveolar hemorrhage due to welding fumes has never defined before.Novel insightsWe herein report a case of alveolar hemorrhage presented with massive hemoptysis due to welding fumes.Clinicians should be aware of such rare but serious clinical picture which can occur in welding workers. Palliative measures and bronchoscopic Ankaferd Blood Stopper® application may help to stop bleeding.

show abstract

A prospective evaluation of hemoptysis cases in a tertiary referral hospital

Cited by 35 publications

References 20 publications

Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer

Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer

Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

Massive hemoptysis due to welding fumes

Contact Info

Product

Resources

About